KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Equity Average: 2019-2025

Historic Equity Average for Adaptive Biotechnologies (ADPT) over the last 6 years, with Sep 2025 value amounting to $192.1 million.

  • Adaptive Biotechnologies' Equity Average fell 17.45% to $192.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.1 million, marking a year-over-year decrease of 17.45%. This contributed to the annual value of $255.6 million for FY2024, which is 33.84% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Equity Average stood at $192.1 million, which was up 3.79% from $185.1 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Equity Average high stood at $734.5 million for Q1 2021, and its period low was $185.1 million during Q2 2025.
  • For the 3-year period, Adaptive Biotechnologies' Equity Average averaged around $285.2 million, with its median value being $258.3 million (2024).
  • As far as peak fluctuations go, Adaptive Biotechnologies' Equity Average spiked by 31.21% in 2021, and later plummeted by 38.59% in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' Equity Average (Quarterly) stood at $627.8 million in 2021, then decreased by 24.18% to $476.0 million in 2022, then fell by 29.61% to $335.1 million in 2023, then crashed by 36.36% to $213.2 million in 2024, then dropped by 17.45% to $192.1 million in 2025.
  • Its Equity Average stands at $192.1 million for Q3 2025, versus $185.1 million for Q2 2025 and $196.6 million for Q1 2025.